Lawrie Conway, Managing Director and CEO at Evolution Mining, discusses the company's business strategy and the outlook for gold prices. He speaks with Shery Ahn and Avril Hong on Bloomberg: The Asia Trade. (Source: Bloomberg)
Lawrie Conway, Managing Director and CEO at Evolution Mining, discusses the company's business strategy and the outlook for gold prices. He speaks with Shery Ahn and Avril Hong on Bloomberg: The Asia Trade. (Source: Bloomberg)
In Brief Ryan Beiermeister, who served as OpenAI’s vice president of product policy, was fired in January after a male colleague accused her of sex discrimination, the Wall Street Journal has reported. “The allegation that I discriminated against anyone is absolutely false,” Beiermeister told the Journal. TechCrunch reached out to OpenAI for comment and also contacted an email that appears to be a...
In Brief Ryan Beiermeister, who served as OpenAI’s vice president of product policy, was fired in January after a male colleague accused her of sex discrimination, the Wall Street Journal has reported. “The allegation that I discriminated against anyone is absolutely false,” Beiermeister told the Journal. TechCrunch reached out to OpenAI for comment and also contacted an email that appears to be associated with Beiermeister; neither had responded at the time of publication. Per the Journal’s report, Beiermeister’s termination came after she expressed criticism of a planned ChatGPT feature dubbed “adult mode.” The new mode would introduce erotica into the chatbot user experience. Fidji Simo, who serves as OpenAI’s CEO of Applications — a role overseeing the company’s consumer-facing products — has told reporters that the new feature is planned to launch during the first quarter of this year. Beiermeister and others at the company have raised concerns about how the new “adult” feature could potentially impact certain users, according to the report. OpenAI reportedly said that Beiermeister, who was fired following a leave of absence, had “made valuable contributions during her time at OpenAI, and her departure was not related to any issue she raised while working at the company.” Beiermeister’s LinkedIn profile says she previously worked for four years on Meta’s product team and spent more than seven years working for Palantir.
Earnings Call Insights: Gilead Sciences, Inc. (GILD) Q4 2025 Management View Daniel O'Day, Chairman & CEO, highlighted "another very strong set of results for Gilead, closing out a remarkable year for the company with clinical, commercial and operational achievements that set the stage for a very promising 2026." He stated the HIV business grew 6% year-over-year, with Biktarvy up 7% and the HIV pr...
Earnings Call Insights: Gilead Sciences, Inc. (GILD) Q4 2025 Management View Daniel O'Day, Chairman & CEO, highlighted "another very strong set of results for Gilead, closing out a remarkable year for the company with clinical, commercial and operational achievements that set the stage for a very promising 2026." He stated the HIV business grew 6% year-over-year, with Biktarvy up 7% and the HIV prevention portfolio up 47%. He noted, "Yeztugo, our twice yearly HIV prevention injectable has already exceeded our coverage goals and is rapidly gaining market share in addition to expanding the reach of HIV prevention to new users." O'Day emphasized up to 10 ongoing and potential new launches through 2027 and called the current clinical pipeline "the strongest pipeline in our almost 40-year history." He said, "With many of the policy-related uncertainties behind us and no major product LOEs until 2036, Gilead is entering 2026 in a position of strength." Andrew Dickinson, Chief Financial Officer, stated, "full year 2025 total product sales of $28.9 billion were up 1% from 2024 and above our $28.4 billion to $28.7 billion guidance range driven by demand-led HIV sales growth that more than offset the $1.1 billion headwind related to Part D redesign and $900 million lower Veklury revenue." Outlook The company expects 2026 total product sales between $29.6 billion and $30 billion. Dickinson said, "We expect base business sales between $29 million and $29.4 billion growth of 4% to 5% compared to 2025." HIV sales, including both treatment and prevention, are projected to grow approximately 6% in 2026. Full year 2026 Yeztugo revenue is expected to reach approximately $800 million compared to $150 million in 2025. Management noted, "absent these headwinds, our HIV business is expected to grow 8% in 2026." The company expects cell therapy revenues to decline approximately 10% in 2026 compared to 2025. Non-GAAP diluted EPS is guided to a range of $8.45 and $8.85 per share for 2026. F...